Molecular Cancer Theraputics: Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium (Houghton, Kurmasheva)

August 3, 2022

Pooja Hingorani Wendong Zhang; Zhongting Zhang; Zhaohui Xu; Wei-Lien Wang; Michael E. Roth Yifei Wang; Jonathan B. Gill Douglas J. Harrison; Beverly A. Teicher; Stephen W. Erickson Gregory Gatto; Edward A. Kolb Malcolm A. Smith Raushan T. Kurmasheva Peter J. Houghton Richard Gorlick Abstract HER2 is expressed in many pediatric solid tumors and is a [...]

Clinical Cancer Research: Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models (Houghton & Kurmasheva)

August 1, 2022

Fuyang Li; Kathryn M. Bondra; Samson Ghilu; Adam Studebaker; Qianqian Liu Joel E. Michalek Mari Kogiso; Xiao-Nan Li John A. Kalapurakal; C. David James; Sandeep Burma; Raushan T. Kurmasheva Peter J. Houghton Abstract Purpose: We investigated why three patient-derived xenografts (PDX) childhood BRAFV600E-mutant brain tumor models are highly sensitive to trametinib. Mechanisms of acquired resistance [...]

Non-Coding RNA: Systematic Analysis of Long Non-Coding RNA Genes in Nonalcoholic Fatty Liver Disease (Bishop Lab)

July 27, 2022

Mirolyuba Ilieva James Dao Henry E. Miller Jens Hedelund Madsen Alexander J. R. Bishop Sakari Kauppinen Shizuka Uchida   Abstract The largest solid organ in humans, the liver, performs a variety of functions to sustain life. When damaged, cells in the liver can regenerate themselves to maintain normal liver physiology. However, some damage is beyond [...]

Neuro – Oncology: ELF4 is a critical component of a miRNA-transcription factor network and is a bridge regulator of glioblastoma receptor signaling and lipid dynamics (Penalva Lab)

July 22, 2022

Adam Kosti, Jennifer Chiou, Gabriela D A Guardia, Xiufen Lei, Henriette Balinda, Tesha Landry, Xiyuan Lu, Mei Qiao, Andrea Gilbert, Andrew Brenner ... Show more Abstract Background The loss of neurogenic tumor suppressor microRNAs miR-124, miR-128, and miR-137 is associated with glioblastoma’s undifferentiated state. Most of their impact comes via the repression of a network of oncogenic transcription factors. We conducted a high-throughput functional siRNA screen [...]

Cell Reports Medicine: A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions (Wang)

July 21, 2022

Cynthia M.Estrada-Zuniga18  Zi-MingCheng18  PurushothEthiraj18  QianjinGuo1  HectorGonzalez-Cantú1  ElainaAdderley2  HectorLopez1  Bethany N.Landry1  AbirZainal2  NeilAronin2  YanliDing3  XiaojingWang45  Ricardo C.T.Aguiar167  Patricia L.M.Dahia169 Highlights • A RET::GRB2 fusion was found in a pheochromocytoma • RET retains its kinase domain, swaps the C tail with GRB2, a normal RET binding partner • RET::GRB2 relies on RET kinase function for transformation • RET::GRB2 renders cells sensitive [...]

Nucleic Acids Research: Quality-controlled R-loop meta-analysis reveals the characteristics of R-loop consensus regions (Bishop Lab)

June 27, 2022

Henry E Miller, Daniel Montemayor, Jebriel Abdul, Anna Vines, Simon A Levy, Stella R Hartono, Kumar Sharma, Bess Frost, Frédéric Chédin, Alexander J R Bishop Abstract R-loops are three-stranded nucleic acid structures formed from the hybridization of RNA and DNA. While the pathological consequences of R-loops have been well-studied to date, the locations, classes, and [...]

BMC Med Informatics & Decision Making: On the Role of Deep Learning Model Complexity in Adversarial Robustness for Medical Images (Chen Lab)

June 21, 2022

David Rodriguez, Tapsya Nayak, Yidong Chen, Ram Krishnan & Yufei Huang Abstract Deep learning (DL) models are highly vulnerable to adversarial attacks for medical image classification. An adversary could modify the input data in imperceptible ways such that a model could be tricked to predict, say, an image that actually exhibits a malignant tumor to a [...]

American Journal of Heart & Circulatory Physiology: Development and Characterization of a Mass Cytometry Panel for Detecting the Effect of Acute Doxorubicin Exposure on Murine Cardiac Non-myocytes (Bishop, Chen, & Aune Labs)

June 8, 2022

Brian S. Iskra, Logan R. Davis, Henry E. Miller, Yu-Chiao Chiu, Alexander J.R. Bishop, Yidong Chen, and Gregory J. Aune Abstract Childhood cancer survivors (CCSs) face lifelong side effects related to their treatment with chemotherapy. Anthracycline agents, such as doxorubicin (DOX), are important in the treatment of childhood cancers but are associated with cardiotoxicity. Cardiac toxicities represent a significant source [...]

Molecular Cancer Therapeutics: Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma (Houghton, Kurmasheva)

June 1, 2022

Yifei Wang; Xiangjun Tian; Wendong Zhang; Zhongting Zhang; Rossana Lazcano; Pooja Hingorani; Michael E. Roth; Jonathan D. Gill; Douglas J. Harrison; Zhaohui Xu; Sylvester Jusu; Sankaranarayanan Kannan; Jing Wang; Alexander J. Lazar; Eric J. Earley; Stephen W. Erickson; Tara Gelb; Philip Huxley; Johanna Lahdenranta; Gemma Mudd; Raushan T. Kurmasheva; Peter J. Houghton; Malcolm A. Smith; [...]

Cancer Letters: The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events (Rao & Chen Labs)

May 18, 2022

Santosh Timilsinaab1 Subapriya Rajamanickambc1 Arhan Raoh Panneerdoss Subbarayaluab Saif Nirzhorab Nourhan Abdelfattahi Suryavathi Viswanadhapallie Yidong Chenbd IsmailJatoif Andrew Brennerg Manjeet K.Raoab Ratna Vadlamudie Virginia Kaklamanig Highlights • Anti-depressant imipramine blocks the growth and progression of breast cancers. • Imipramine induces cell cycle arrest and blocks heightened DNA repair activities in breast cancer cells. • Imipramine [...]